VIVA BIOTECH (01873) saw its shares climb nearly 7% during the trading session. As of the time of writing, the stock was up 4.21%, trading at HKD 1.98, with a turnover of HKD 16.048 million. According to an announcement on VIVA BIOTECH's official social media account, on January 13th, the company hosted an innovation symposium during the 44th J.P. Morgan Healthcare Conference, which attracted numerous professionals for exchanges. The symposium focused on cutting-edge advancements in artificial intelligence and novel drug modalities. VIVA BIOTECH shared insights on AI-empowered experimental design for the entire peptide drug R&D process and its AI-enhanced peptide CRDMO platform. This highlighted how artificial intelligence is accelerating implementation in critical R&D and industrialization phases, becoming a significant highlight of the event. Huaxin Securities previously issued a research note stating that VIVA BIOTECH's CRO business primarily serves the early stages of drug discovery, a key area for AI application that can enhance the efficiency and success rate of drug development. Consequently, the company has launched an integrated AI-driven drug discovery platform, AIDD, for its clients. As of the first half of 2025, the AIDD platform has been involved in the development of 175 projects, with AI-enabled CRO services accounting for 10% of total revenue.